{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:29:11Z","timestamp":1792214951649,"version":"4.4.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005881","name":"Ministry of Culture and Innovation","doi-asserted-by":"publisher","award":["TKP2021-EGA-32"],"award-info":[{"award-number":["TKP2021-EGA-32"]}],"id":[{"id":"10.13039\/501100005881","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015763","name":"University of Szeged","doi-asserted-by":"publisher","award":["EK\\u00D6P-24-3-SZTE-221"],"award-info":[{"award-number":["EK\\u00D6P-24-3-SZTE-221"]}],"id":[{"id":"10.13039\/501100015763","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012550","name":"Nemzeti Kutat\u00e1si, Fejleszt\u00e9si \u00e9s Innovaci\u00f3s Alap","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012550","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ejpb.2025.114743","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T13:05:07Z","timestamp":1746795907000},"page":"114743","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Ceftriaxone-loaded albumin-based nanoparticles incorporated into in situ ionic sensitive nasal gels: Development, characterization, and nasal drug deposition studies"],"prefix":"10.1016","volume":"212","author":[{"given":"Sandra Aulia","family":"Mardikasari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"Katona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Ni\u017ei\u0107","family":"Nodilo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Hafner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livije","family":"Kalogjera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dijana","family":"Zadravec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"Orosz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Burian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy Tibor","family":"Balogh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ildik\u00f3","family":"Cs\u00f3ka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2025.114743_b0005","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.cmi.2016.01.007","article-title":"ESCMID guideline: Diagnosis and treatment of acute bacterial meningitis","volume":"22","author":"van de Beek","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.ejpb.2025.114743_b0010","doi-asserted-by":"crossref","unstructured":"A.M.J. Griffiths, C.F.M. D, T.S. G, Management of acute meningitis, Clin. Med. (Northfield. Il). 18 (2018) 164\u2013169.","DOI":"10.7861\/clinmedicine.18-2-164"},{"key":"10.1016\/j.ejpb.2025.114743_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.00634-19","article-title":"High-dose ceftriaxone for bacterial meningitis and optimization of administration scheme based on nomogram","volume":"63","author":"Gr\u00e9goire","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2025.114743_b0020","unstructured":"WHO, Meningitis, (2023). https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/meningitis (accessed 24 June 2024)."},{"key":"10.1016\/j.ejpb.2025.114743_b0025","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/1756285609337975","article-title":"Pathophysiology and treatment of bacterial meningitis","volume":"2","author":"Hoffman","year":"2009","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.ejpb.2025.114743_b0030","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2217\/fmb.12.1","article-title":"Defense at the border: The blood-brain barrier versus bacterial foreigners","volume":"7","author":"Van Sorge","year":"2012","journal-title":"Future Microbiol."},{"key":"10.1016\/j.ejpb.2025.114743_b0035","doi-asserted-by":"crossref","unstructured":"R.M. Hathout, S.G. Abdelhamid, G.S. El-Housseiny, A.A. Metwally, Hathout, 2020 - Comparing cefotaxime and ceftriaxone in combating meningitis through nose to brain delivery using biochemoinformatics tools.pdf, n.d.","DOI":"10.1038\/s41598-020-78327-w"},{"key":"10.1016\/j.ejpb.2025.114743_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114502","article-title":"Strategies and progresses for enhancing targeted antibiotic delivery","volume":"189","author":"Nazli","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2025.114743_b0045","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ejpb.2018.05.009","article-title":"Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics","volume":"128","author":"Bourganis","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2025.114743_b0050","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.trci.2018.06.012","article-title":"Intranasal rifampicin for Alzheimer\u2019s disease prevention","volume":"4","author":"Umeda","year":"2018","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"10.1016\/j.ejpb.2025.114743_b0055","article-title":"Nose-to-brain drug delivery: Challenges and progress towards brain targeting in the treatment of neurological disorders","volume":"86","author":"Raghav","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejpb.2025.114743_b0060","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s10787-018-0468-y","article-title":"Enhancement of drug permeability across blood brain barrier using nanoparticles in meningitis","volume":"26","author":"Nair","year":"2018","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.ejpb.2025.114743_b0065","article-title":"On a highway to the brain: A review on nose-to-brain drug delivery using nanoparticles","volume":"29","author":"Formica","year":"2022","journal-title":"Appl. Mater. Today."},{"key":"10.1016\/j.ejpb.2025.114743_b0070","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1463976","article-title":"Recent developments in intranasal drug delivery of nanomedicines for the treatment of neuropsychiatric disorders","volume":"11","author":"Kisku","year":"2024","journal-title":"Front. Med."},{"key":"10.1016\/j.ejpb.2025.114743_b0075","doi-asserted-by":"crossref","unstructured":"S.A. Mardikasari, G. Katona, I. Cs\u00f3ka, Serum Albumin in Nasal Drug Delivery Systems\u00a0: Exploring the Role and Application, Pharmaceutics. 16 (2024) 1\u20136. https:\/\/doi.org\/10.3390\/pharmaceutics16101322.","DOI":"10.3390\/pharmaceutics16101322"},{"key":"10.1016\/j.ejpb.2025.114743_b0080","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1080\/17425247.2016.1193149","article-title":"Albumin nanostructures as advanced drug delivery systems","volume":"13","author":"Karimi","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2025.114743_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-021-00896-3","article-title":"Protein nanoparticles in drug delivery: animal protein, plant proteins and protein cages, albumin nanoparticles","volume":"19","author":"Kianfar","year":"2021","journal-title":"J. Nanobiotechnology."},{"key":"10.1016\/j.ejpb.2025.114743_b0090","first-page":"697","article-title":"A new nanobiotic: synthesis and characterization of an albumin nanoparticle with intrinsic antibiotic activity","volume":"15","author":"Hosseini","year":"2023","journal-title":"Iran. J. Microbiol."},{"key":"10.1016\/j.ejpb.2025.114743_b0095","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1080\/17425247.2018.1517741","article-title":"In situ gelling and mucoadhesive polymers: why do they need each other?","volume":"15","author":"Zahir-Jouzdani","year":"2018","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2025.114743_b0100","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ijpharm.2008.08.042","article-title":"In situ gel based on gellan gum as new carrier for nasal administration of mometasone furoate","volume":"365","author":"Lei Cao","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114743_b0105","first-page":"1","article-title":"Ionotropic gelation and chemical crosslinking as methods for fabrication of modified-release gellan gum-based drug delivery systems","volume":"15","author":"Gadzi\u0144ski","year":"2023","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.ejpb.2025.114743_b0110","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14071353","article-title":"In vitro anatomical models for nasal drug delivery","volume":"14","author":"Williams","year":"2022","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.ejpb.2025.114743_b0115","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15061660","article-title":"Chitosan-based thermogelling system for nose-to-brain donepezil delivery: optimising formulation properties and nasal deposition profile","volume":"15","author":"Perku\u0161i\u0107","year":"2023","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.ejpb.2025.114743_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics15061720","article-title":"The upper nasal space: option for systemic drug delivery, mucosal vaccines and \u201cnose-to-brain\u201d","volume":"15","author":"Shrewsbury","year":"2023","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.ejpb.2025.114743_b0125","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13071079","article-title":"In vitro evaluation of nasal aerosol depositions: An insight for direct nose to brain drug delivery","volume":"13","author":"Maaz","year":"2021","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.ejpb.2025.114743_b0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0086593","article-title":"Electrophoretic particle guidance significantly enhances olfactory drug delivery: A feasibility study","volume":"9","author":"Xi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2025.114743_b0135","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.ijbiomac.2016.05.032","article-title":"A simple improved desolvation method for the rapid preparation of albumin nanoparticles","volume":"91","author":"Jahanban-Esfahlan","year":"2016","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejpb.2025.114743_b0140","doi-asserted-by":"crossref","DOI":"10.3390\/gels8110750","article-title":"Development of thermoresponsive-gel-matrix-embedded amoxicillin trihydrate-loaded bovine serum albumin nanoparticles for local intranasal therapy","volume":"8","author":"Mardikasari","year":"2022","journal-title":"Gels."},{"key":"10.1016\/j.ejpb.2025.114743_b0145","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s13738-019-01850-9","article-title":"Effect of different cross-linking agents on the preparation of bovine serum albumin nanoparticles","volume":"17","author":"Amighi","year":"2020","journal-title":"J. Iran. Chem. Soc."},{"key":"10.1016\/j.ejpb.2025.114743_b0150","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ijbiomac.2016.02.044","article-title":"Ion activated in situ gel of gellan gum containing salbutamol sulphate for nasal administration","volume":"87","author":"Salunke","year":"2016","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejpb.2025.114743_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123435","article-title":"Quality by design-based optimization of in situ ionic-sensitive gels of amoxicillin-loaded bovine serum albumin nanoparticles for enhanced local nasal delivery","volume":"645","author":"Mardikasari","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114743_b0160","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ijpharm.2018.07.014","article-title":"A novel nasal almotriptan loaded solid lipid nanoparticles in mucoadhesive in situ gel formulation for brain targeting: Preparation, characterization and in vivo evaluation","volume":"548","author":"Youssef","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114743_b0165","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1039\/C9NJ05847H","article-title":"BSA nanoparticles as controlled release carriers for isophethalaldoxime palladacycle complex; Synthesis, characterization,: In vitro evaluation, cytotoxicity and release kinetics analysis","volume":"44","author":"Karami","year":"2020","journal-title":"New J. Chem."},{"key":"10.1016\/j.ejpb.2025.114743_b0170","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.colsurfb.2016.08.011","article-title":"Fabrication of an ionic-sensitive in situ gel loaded with resveratrol nanosuspensions intended for direct nose-to-brain delivery","volume":"147","author":"Hao","year":"2016","journal-title":"Colloids Surfaces B Biointerfaces."},{"key":"10.1016\/j.ejpb.2025.114743_b0175","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ijpharm.2014.08.064","article-title":"Intranasal in situ gel loaded with saquinavir mesylate nanosized microemulsion: Preparation, characterization, and in vivo evaluation","volume":"475","author":"Hosny","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114743_b0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics12080697","article-title":"Quality by design based formulation study of meloxicam-loaded polymeric micelles for intranasal administration","volume":"12","author":"Sipos","year":"2020","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.ejpb.2025.114743_b0185","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1080\/10837450.2018.1514523","article-title":"Montelukast nasal spray: formulation development and in vitro evaluation","volume":"24","author":"Jullaphant","year":"2019","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejpb.2025.114743_b0190","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1007\/s11095-011-0417-6","article-title":"Effect of formulation- and administration-related variables on deposition pattern of nasal spray pumps evaluated using a nasal cast","volume":"28","author":"Kundoor","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2025.114743_b0195","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1080\/02786826.2014.931566","article-title":"A comparison of the deposition patterns of different nasal spray formulations using a nasal cast","volume":"48","author":"Pu","year":"2014","journal-title":"Aerosol Sci. Technol."},{"key":"10.1016\/j.ejpb.2025.114743_b0200","doi-asserted-by":"crossref","unstructured":"A. Avdeef, Permeability\u2014 pampa, in: Absorpt. Drug Dev. Solubility, Permeability, Charg. State, Second Ed., John Wiley & Sons, Inc., Hoboken, NJ, USA, 2012: pp. 319\u2013498.","DOI":"10.1002\/9781118286067.ch7"},{"key":"10.1016\/j.ejpb.2025.114743_b0205","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jpha.2015.11.005","article-title":"Methods for in vitro evaluating antimicrobial activity: A review","volume":"6","author":"Balouiri","year":"2016","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.ejpb.2025.114743_b0210","first-page":"1","article-title":"A Dry powder platform for nose-to-brain delivery of dexamethasone: formulation development and nasal deposition studies","volume":"13","author":"Nodilo","year":"2021","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.ejpb.2025.114743_b0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/polym13213759","article-title":"Serum albumin nanoparticles: Problems and prospects","volume":"13","author":"Hornok","year":"2021","journal-title":"Polymers (Basel)."},{"key":"10.1016\/j.ejpb.2025.114743_b0220","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1021\/acs.molpharmaceut.1c00046","article-title":"The uniqueness of albumin as a carrier in nanodrug delivery","volume":"18","author":"Spada","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2025.114743_b0225","doi-asserted-by":"crossref","first-page":"14175","DOI":"10.1021\/acs.jmedchem.4c00983","article-title":"Interaction of cephalosporins with human serum albumin: A structural study","volume":"67","author":"Kawai","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejpb.2025.114743_b0230","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.1021\/acsomega.0c00111","article-title":"Developing biodegradable nanoparticles loaded with mometasone furoate for potential nasal drug delivery","volume":"5","author":"Far","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejpb.2025.114743_b0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fchem.2020.00286","article-title":"Nano-based drug delivery or targeting to eradicate bacteria for infection mitigation: A review of recent advances","volume":"8","author":"Yeh","year":"2020","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejpb.2025.114743_b0240","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1071\/EN09115","article-title":"Bacteria-nanoparticle interactions and their environmental implications","volume":"7","author":"Aruguete","year":"2010","journal-title":"Environ. Chem."},{"key":"10.1016\/j.ejpb.2025.114743_b0245","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11051-006-9150-1","article-title":"Investigation into the antibacterial behaviour of suspensions of ZnO nanoparticles (ZnO nanofluids)","volume":"9","author":"Zhang","year":"2007","journal-title":"J. Nanoparticle Res."},{"key":"10.1016\/j.ejpb.2025.114743_b0250","first-page":"1","article-title":"Direct nose to the brain nanomedicine delivery presents a formidable challenge, Wiley Interdiscip. Rev. Nanomedicine","volume":"14","author":"Yokel","year":"2022","journal-title":"NanoBiotechnology"},{"key":"10.1016\/j.ejpb.2025.114743_b0255","doi-asserted-by":"crossref","DOI":"10.3390\/ma15196547","article-title":"Excipients used for modified nasal drug delivery: A mini-review of the recent advances","volume":"15","author":"Protopapa","year":"2022","journal-title":"Materials (Basel)."},{"key":"10.1016\/j.ejpb.2025.114743_b0260","doi-asserted-by":"crossref","first-page":"454","DOI":"10.2500\/ajra.2014.28.4092","article-title":"The effect of drugs and other compounds on the ciliary beat frequency of human respiratory epithelium","volume":"28","author":"Workman","year":"2014","journal-title":"Am. J. Rhinol. Allergy."},{"key":"10.1016\/j.ejpb.2025.114743_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.tiv.2020.104865","article-title":"Ciliary beat frequency of in vitro human nasal epithelium measured with the simple high-speed microscopy is applicable for safety studies of nasal drug formulations","volume":"66","author":"Tratnjek","year":"2020","journal-title":"Toxicol. Vitr."},{"key":"10.1016\/j.ejpb.2025.114743_b0270","first-page":"1","article-title":"Physiology and pathophysiology of respiratory mucosa of the nose and the paranasal sinuses, GMS Curr","volume":"9","author":"Beule","year":"2010","journal-title":"Top. Otorhinolaryngol. - Head Neck Surg."},{"key":"10.1016\/j.ejpb.2025.114743_b0275","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2273.1999.00223.x","article-title":"Nasal pH measurement: A reliable and repeatable parameter","volume":"24","author":"England","year":"1999","journal-title":"Clin. Otolaryngol. Allied Sci."},{"key":"10.1016\/j.ejpb.2025.114743_b0280","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0378-5173(99)00442-1","article-title":"Determination of baseline human nasal pH and the effect of intranasally administered buffers","volume":"198","author":"Washington","year":"2000","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114743_b0285","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.msec.2017.03.002","article-title":"Quality by Design approach for an in situ gelling microemulsion of Lorazepam via intranasal route","volume":"75","author":"Shah","year":"2017","journal-title":"Mater. Sci. Eng. c."},{"key":"10.1016\/j.ejpb.2025.114743_b0290","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13030385","article-title":"Nasal powder formulations: In-vitro characterisation of the impact of powders on nasal residence time and sensory effects","volume":"13","author":"Trenkel","year":"2021","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.ejpb.2025.114743_b0295","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1089\/jamp.2011.0924","article-title":"Nasal deposition and clearance in man: Comparison of a bidirectional powder device and a traditional liquid spray pump","volume":"25","author":"Djupesland","year":"2012","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.ejpb.2025.114743_b0300","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.addr.2020.09.002","article-title":"In vitro \u2013 in vivo correlation of intranasal drug deposition","volume":"170","author":"Le Guellec","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2025.114743_b0305","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3390\/pharmaceutics6020195","article-title":"Analytical challenges and regulatory requirements for nasal drug products in Europe and the U.S","volume":"6","author":"Trows","year":"2014","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.ejpb.2025.114743_b0310","unstructured":"EMA, Guideline on the Pharmaceutical Quality of Inhalation and Nasal Products, London, 2006."},{"key":"10.1016\/j.ejpb.2025.114743_b0315","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40005-020-00482-z","article-title":"Factors influencing drug deposition in the nasal cavity upon delivery via nasal sprays","volume":"50","author":"Gao","year":"2020","journal-title":"J. Pharm. Investig."},{"key":"10.1016\/j.ejpb.2025.114743_b0320","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1080\/17425247.2019.1597051","article-title":"Smart thermosensitive chitosan hydrogel for nasal delivery of ibuprofen to treat neurological disorders","volume":"16","author":"Gholizadeh","year":"2019","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2025.114743_b0325","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1080\/02786826.2024.2332633","article-title":"Spatial and temporal characterization of droplet diameter and velocities of a nasal spray atomization","volume":"58","author":"Van Strien","year":"2024","journal-title":"Aerosol Sci. Technol."},{"key":"10.1016\/j.ejpb.2025.114743_b0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaerosci.2022.106009","article-title":"Spray characteristics from nasal spray atomization","volume":"165","author":"Van Strien","year":"2022","journal-title":"J. Aerosol Sci."},{"key":"10.1016\/j.ejpb.2025.114743_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijmultiphaseflow.2022.104219","article-title":"Droplet size distribution in swirl nozzles","volume":"156","author":"Chen","year":"2022","journal-title":"Int. J. Multiph. Flow."},{"key":"10.1016\/j.ejpb.2025.114743_b0340","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/cite.202200152","article-title":"Influence of nozzle parameters on spray pattern and droplet characteristics for a two-fluid nozzle","volume":"95","author":"Kramm","year":"2023","journal-title":"Chem.-Ing.-Tech."},{"key":"10.1016\/j.ejpb.2025.114743_b0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113826","article-title":"The importance of pre-formulation studies and of 3D-printed nasal casts in the success of a pharmaceutical product intended for nose-to-brain delivery","volume":"175","author":"Deruyver","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2025.114743_b0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123345","article-title":"In situ hydrogel containing diazepam-loaded nanostructured lipid carriers (DZP-NLC) for nose-to-brain delivery: development, characterization and deposition studies in a 3D-printed human nasal cavity model","volume":"644","author":"Pina Costa","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114743_b0355","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.apsb.2021.02.012","article-title":"Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: A current overview of in vivo studies","volume":"11","author":"Costa","year":"2021","journal-title":"Acta Pharm. Sin. B."},{"key":"10.1016\/j.ejpb.2025.114743_b0360","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/jac\/dki323","article-title":"Evaluation of ceftriaxone, vancomycin and rifampicin alone and combined in an experimental model of meningitis caused by highly cephalosporin-resistant Streptococcus pneumoniae ATCC 51916","volume":"56","author":"Ribes","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejpb.2025.114743_b0365","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1469-0691.2006.01352.x","article-title":"Combined treatment with ceftriaxone and linezolid of pneumococcal meningitis: A case series including penicillin-resistant strains","volume":"12","author":"Faella","year":"2006","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.ejpb.2025.114743_b0370","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1093\/jac\/dkab215","article-title":"Bactericidal activities and post-antibiotic effects of ofloxacin and ceftriaxone against drug-resistant Salmonella enterica serovar Typhi","volume":"76","author":"Wain","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejpb.2025.114743_b0375","first-page":"1","article-title":"Enhanced bactericidal effect of ceftriaxone drug encapsulated in nanostructured lipid carrier against gram-negative Escherichia coli bacteria: Drug formulation, optimization, and cell culture study, Antimicrob. Resist","volume":"9","author":"Ebrahimi","year":"2020","journal-title":"Infect. Control."},{"key":"10.1016\/j.ejpb.2025.114743_b0380","first-page":"1","article-title":"Bactericidal versus bacteriostatic antibacterials\u00a0: clinical significance, differences and synergistic potential in clinical practice","author":"Ishak","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejpb.2025.114743_b0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pathogens10020165","article-title":"The minimum inhibitory concentration of antibiotics: Methods, interpretation, clinical relevance","volume":"10","author":"Kowalska-Krochmal","year":"2021","journal-title":"Pathogens."},{"key":"10.1016\/j.ejpb.2025.114743_b0390","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.mimet.2009.07.017","article-title":"Variations in MIC value caused by differences in experimental protocol","volume":"79","author":"Schuurmans","year":"2009","journal-title":"J. Microbiol. Methods."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641125001201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641125001201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T08:40:48Z","timestamp":1762332048000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641125001201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":78,"alternative-id":["S0939641125001201"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2025.114743","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ceftriaxone-loaded albumin-based nanoparticles incorporated into in situ ionic sensitive nasal gels: Development, characterization, and nasal drug deposition studies","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2025.114743","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114743"}}